Polo-like kinase inhibitor volasertib marginally enhances the efficacy of the novel Fc-engineered anti-CD33 antibody BI 836858 in acute myeloid leukemia

por Gopalakrishnan, Bhavani, Cheney, Carolyn, Mani, Rajeswaran, Mo, Xiaokui, Bucci, Donna, Walker, Alison, Klisovic, Rebecca, Bhatnagar, Bhavana, Walsh, Katherine, Rueter, Bjoern, Waizenegger, Irene C., Heider, Karl-Heinz, Blum, William, Vasu, Sumithira, Muthusamy, Natarajan
Publicado 2018

Somatic mutational landscape of AML with inv(16) or t(8;21) identifies patterns of clonal evolution in relapse leukemia

por Sood, Raman, Hansen, Nancy F., Donovan, Frank X., Carrington, Blake, Bucci, Donna, Maskeri, Baishali, Young, Alice, Trivedi, Niraj S., Kohlschmidt, Jessica, Stone, Richard M., Caligiuri, Michael A., Chandrasekharappa, Settara C., Marcucci, Guido, Mullikin, James C., Bloomfield, Clara D., Liu, Paul
Publicado 2015

The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34(+)CD123(+) cells from acute myeloid leukemia/myelodysplastic syndrome patients and...

por Mani, Rajeswaran, Goswami, Swagata, Gopalakrishnan, Bhavani, Ramaswamy, Rahul, Wasmuth, Ronni, Tran, Minh, Mo, Xiaokui, Gordon, Amber, Bucci, Donna, Lucas, David M., Mims, Alice, Brooks, Christopher, Dorrance, Adrienne, Walker, Alison, Blum, William, Byrd, John C., Lozanski, Gerard, Vasu, Sumithira, Muthusamy, Natarajan
Publicado 2018

TREATMENT WITH SOLUBLE CD24 ATTENUATES COVID-19-ASSOCIATED SYSTEMIC IMMUNOPATHOLOGY

por Song, No-Joon, Allen, Carter, Vilgelm, Anna E., Riesenberg, Brian P., Weller, Kevin P., Reynolds, Kelsi, Chakravarthy, Karthik B., Kumar, Amrendra, Khatiwada, Aastha, Sun, Zequn, Ma, Anjun, Chang, Yuzhou, Yusuf, Mohamed, Li, Anqi, Zeng, Cong, Evans, John P., Bucci, Donna, Gunasena, Manuja, Xu, Menglin, Liyanage, Namal P.M., Bolyard, Chelsea, Velegraki, Maria, Liu, Shan-Lu, Ma, Qin, Devenport, Martin, Liu, Yang, Zheng, Pan, Malvestutto, Carlos D., Chung, Dongjun, Li, Zihai
Publicado 2021

Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology

por Song, No-Joon, Allen, Carter, Vilgelm, Anna E., Riesenberg, Brian P., Weller, Kevin P., Reynolds, Kelsi, Chakravarthy, Karthik B., Kumar, Amrendra, Khatiwada, Aastha, Sun, Zequn, Ma, Anjun, Chang, Yuzhou, Yusuf, Mohamed, Li, Anqi, Zeng, Cong, Evans, John P., Bucci, Donna, Gunasena, Manuja, Xu, Menglin, Liyanage, Namal P. M., Bolyard, Chelsea, Velegraki, Maria, Liu, Shan-Lu, Ma, Qin, Devenport, Martin, Liu, Yang, Zheng, Pan, Malvestutto, Carlos D., Chung, Dongjun, Li, Zihai
Publicado 2022

Selective suppression of de novo SARS-CoV-2 vaccine antibody responses in patients with cancer on B cell–targeted therapy

por Azar, Joseph H., Evans, John P., Sikorski, Madison H., Chakravarthy, Karthik B., McKenney, Selah, Carmody, Ian, Zeng, Cong, Teodorescu, Rachael, Song, No-Joon, Hamon, Jamie L., Bucci, Donna, Velegraki, Maria, Bolyard, Chelsea, Weller, Kevin P., Reisinger, Sarah A., Bhat, Seema A., Maddocks, Kami J., Denlinger, Nathan, Epperla, Narendranath, Gumina, Richard J., Vlasova, Anastasia N., Oltz, Eugene M., Saif, Linda J., Chung, Dongjun, Woyach, Jennifer A., Shields, Peter G., Liu, Shan-Lu, Li, Zihai, Rubinstein, Mark P.
Publicado 2023